Macrophage activation through phagocytosis of muramyl dipeptide encapsulated in gelatin microspheres

Area of Science:

• Biotechnology
• Immunology
• Materials Science

Background:

• Muramyl dipeptide (MDP) is known to activate macrophages, but its therapeutic application is limited by low efficiency and short duration.
• Developing effective delivery systems for immunomodulatory agents like MDP is crucial for cancer therapy.

Purpose of the Study:

• To develop gelatin microspheres for encapsulating MDP and evaluate their efficacy in activating mouse peritoneal macrophages (PMs) for tumor growth inhibition.
• To compare the potency, duration, and in vivo activity of MDP-loaded microspheres with free MDP.

Main Methods:

• Gelatin microspheres were prepared by crosslinking with glutaraldehyde and loaded with MDP.
• Mouse peritoneal macrophages (PMs) were incubated with microsphere-encapsulated MDP or free MDP.
• Tumor growth inhibitory activity of activated PMs was assessed against syngeneic, allogeneic, and xenogeneic tumor cells.
• In vivo activity was evaluated after intraperitoneal injection of microspheres.

Main Results:

• MDP-loaded gelatin microspheres enhanced the tumor growth inhibitory activity of PMs.
• Microsphere-encapsulated MDP was more efficient and activated PMs faster than free MDP.
• The duration of PM activity could be controlled up to 7 days by adjusting microsphere crosslinking.
• Microsphere-encapsulated MDP activated PMs at concentrations ~2000 times lower than free MDP.
• In vivo administration of microspheres activated PMs, unlike free MDP.

Conclusions:

• Gelatin microspheres provide a highly efficient delivery system for MDP, significantly enhancing macrophage-mediated tumor growth inhibition.
• This approach offers controlled duration of activity and superior in vivo efficacy compared to free MDP, suggesting potential for cancer immunotherapy.